Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-2650PMID 17332275
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

  2007cited by this paper
• Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients

  2007cited by this paper
• Enhancement of clonogenicity of human multiple myeloma by dendritic cells

  2006cited by this paper
• Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.

  2006cited by this paper
• Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.

  2006cited by this paper
• In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.

  2006cited by this paper
• Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

  2006cited by this paper
• Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

  2005cited by this paper
• Differentiation and Expansion of T Cells with Regulatory Function from Human Peripheral Lymphocytes by Stimulation in the Presence of TGF-β

  2005cited by this paper
• Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

  2005cited by this paper
• Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

  2005cited by this paper
• Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1‐like regulatory T cells

  2005cited by this paper
• Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma.

  2004cited by this paper
• Either interleukin‐12 or interferon‐γ can correct the dendritic cell defect induced by transforming growth factor β1 in patients with myeloma

  2004cited by this paper
• Fatal attraction: tumors beckon regulatory T cells

  2004cited by this paper
• Immune Recovery of Lymphocyte Subsets 6 Years after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoproliferative Diseases. A Comparison between NHL, HD and MM in Group of 149 Patients

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.

  2003cited by this paper
• T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma.

  2003cited by this paper
• Dendritic Cell-based Immunotherapy in Multiple Myeloma

  2003cited by this paper
• Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

  2002cited by this paper
• Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.

  2001cited by this paper
• Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.

  2001cited by this paper
• Topoisomerase I Inhibitors with an Indolocarbazole Structure Transporter as a Transporter of NB-506 and J-107088 , Resistance / Placenta-Specific , ATP-binding Cassette Identification of Breast Cancer Resistant Protein / Mitoxantrone Updated

  2001cited by this paper
• Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

  2001cited by this paper
• Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells

  2000cited by this paper
• Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

  1999cited by this paper
• Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation.

  1999cited by this paper
• Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.

  1999cited by this paper
• Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.

  1999cited by this paper
• Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma

  1999cited by this paper
• IL-12 acts selectively on CD8 alpha- dendritic cells to enhance presentation of a tumor peptide in vivo.

  1999cited by this paper
• Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody

  1999cited by this paper
• Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.

  1998cited by this paper
• Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation.

  1998cited by this paper
• Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.

  1997cited by this paper
• Idiotype‐specific T cells in multiple myeloma stage I: an evaluation by four different functional tests

  1995cited by this paper
• Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies

  1995cited by this paper
• Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies.

  1995cited by this paper
• Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.

  1994cited by this paper
• Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy.

  1978cited by this paper

• Advances and challenges in anti-cancer vaccines for multiple myeloma

  2024cites this paper
• Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties

  2024cites this paper
• Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens

  2022cites this paper
• Boosting Immunity against Multiple Myeloma

  2021cites this paper
• Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

  2021cites this paper
• The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

  2021cites this paper
• Immunotherapy of multiple myeloma.

  2020cites this paper
• The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

  2018cites this paper
• PD-L1-specific T cells

  2016cites this paper
• Phase I/II study exploring ImMucin, a pan‐major histocompatibility complex, anti‐MUC1 signal peptide vaccine, in multiple myeloma patients

  2015cites this paper
• Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

  2015cites this paper
• Assessment of peripheral blood and bone marrow T, NK, NKT and dendritic cells in patients with multiple myeloma.

  2015cites this paper
• Phase I / II study exploring ImMucin , a pan-major histocompatibility complex , anti-MUC 1 signal peptide vaccine , in multiple myeloma patients

  2014cites this paper
• Dendritic Cells and Peptide-Based Vaccine In Multiple Myeloma

  2013cites this paper
• Defining Multiple Myeloma as a Target for DNA Vaccines

  2013cites this paper
• Advances in Biology and Therapy of Multiple Myeloma

  2013cites this paper
• Trial watch

  2012cites this paper
• Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma

  2012cites this paper
• Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.

  2011cites this paper
• High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma.

  2011cites this paper
• Turning up the heat on myeloma

  2009cites this paper
• Turning up the heat on myeloma.

  2009cites this paper
• Turning up the heat on myeloma

  2009cites this paper
• The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease.

  2008cites this paper
• Future challenges

  2007cites this paper